Monocyte membrane ferritin in hemochromatosis

• Published in: Clinical and investigative medicine Vol. 14; no. 5; pp. 402 - 408
• Main Authors: ADAMS, P. C, FLANAGAN, P. R, CHAU, L, WHITE, M, LAZAROVITZ, A
• Format: Journal Article
• Language: English
• Published: Toronto, ON Canadian Medical Association 01.10.1991
• Subjects: Antibodies, Monoclonal; Biological and medical sciences; Cell Membrane - metabolism; Ferritins - blood; Ferritins - immunology; Flow Cytometry; Hematology; Hemochromatosis - blood; Humans; Immunoassay; Investigative techniques, diagnostic techniques (general aspects); Liver - chemistry; Medical sciences; Monocytes - metabolism; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques; Human; Ferroprotein; Hemochromatosis; Monocyte; Immunological investigation; Ferritin; Plasma membrane; Hemopathy; Monoclonal antibody; Genetic disease
• ISSN: 0147-958X; 1488-2353

To further evaluate a possible abnormality in the reticuloendothelial cells in hemochromatosis, the binding of a monoclonal anti-human liver ferritin antibody to monocytes was studied in 19 patients with hemochromatosis, 8 patients with secondary iron overload, 1 patient with hyperferritinemia without iron overload, and 15 normal volunteers. Binding of the antibody to the monocytes was analyzed using a fluorescence-activated cell sorter (FACS). Binding of the anti-ferritin antibody to monocytes was demonstrated in 34.7 +/- 4.5% (mean +/- standard error) of the monocytes in untreated hemochromatosis patients (mean serum ferritin = 2294 +/- 415 micrograms/L), 6.75 +/- 2.03% in treated hemochromatosis patients (mean serum ferritin = 263 +/- 85 micrograms/L), 12.3 +/- 2.7% of the monocytes in the secondary iron overload patients (mean serum ferritin = 2476 +/- 867 micrograms/L), 4.1% in the patient with hyperferritinemia (serum ferritin = 1192) and 4.1 +/- 0.5% of the monocytes in the normal volunteers (mean serum ferritin = 55.2 +/- 11.9 micrograms/L). % binding of anti-ferritin antibody was significantly greater in hemochromatosis patients compared to patients with secondary iron overload (p less than 0.05) despite a comparable degree of iron overload in the secondary iron overload group. The addition of exogenous human ferritin to samples from treated hemochromatosis patients and normal volunteers did not significantly increase the % of monocytes binding anti-ferritin antibody. These results suggest that monocytes from iron-loaded hemochromatosis patients express increased surface ferritin which may represent release of ferritin and a metabolic defect characteristic of hemochromatosis.